Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Biofrontera Inc. (BFRI : NSDQ)

• Company Description    Biofrontera Inc. is a biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on the fields of photodynamic therapy and topical antibiotics. The Company's licensed products focus on the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Biofrontera Inc. is based in WOBURN, MA. Number of Employees: 93

• Price / Volume Information    Yesterday's Closing Price: $0.86 Daily Weekly Monthly 20 Day Moving Average: 192,470 shares Shares Outstanding: 9.45 (millions) Market Capitalization: $8.12 (millions) Beta: 0.43 52 Week High: $1.54 52 Week Low: $0.54 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 32.31% 27.77% 12 Week 1.18% -14.62% Year To Date -21.10% -27.14%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 120 PRESIDENTIAL WAY SUITE 330 - WOBURN,MA 01801 USA ph: 781-245-1325 fax: - ir@bfinc.com http://www.biofrontera.us.com

• General Corporate Information    Officers Hermann Lubbert - Chief Executive Officer and Chairman E. Fred Leffler - Chief Financial Officer John J. Borer - Director Beth J. Hoffman - Director Heikki Lanckriet - Director Peer Information Biofrontera Inc. (CORR.) Biofrontera Inc. (RSPI) Biofrontera Inc. (CGXP) Biofrontera Inc. (BGEN) Biofrontera Inc. (GTBP) Biofrontera Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 09077D209 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/13/25 Share - Related Items Shares Outstanding: 9.45 Most Recent Split Date: 7.00 (0.05:1) Beta: 0.43 Market Capitalization: $8.12 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.28 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.97 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 17.32 Price/Cash Flow: - Price / Sales: 0.21 EPS Growth vs. Year Ago Period: 74.59% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: 8.54% vs. Previous Quarter: -31.61% ROE 06/30/25 - - 03/31/25 - -305.13 12/31/24 - -485.70 ROA 06/30/25 - - 03/31/25 - -82.67 12/31/24 - -86.53 Current Ratio 06/30/25 - - 03/31/25 - 1.40 12/31/24 - 1.72 Quick Ratio 06/30/25 - - 03/31/25 - 0.80 12/31/24 - 1.17 Operating Margin 06/30/25 - - 03/31/25 - -42.85 12/31/24 - -50.29 Net Margin 06/30/25 - - 03/31/25 - -30.33 12/31/24 - -47.58 Pre-Tax Margin 06/30/25 - - 03/31/25 - -30.28 12/31/24 - -47.53 Book Value 06/30/25 - - 03/31/25 - 0.05 12/31/24 - 0.57 Inventory Turnover 06/30/25 - - 03/31/25 - 3.00 12/31/24 - 3.10 Debt-to-Equity 06/30/25 - - 03/31/25 - 8.99 12/31/24 - 0.92 Debt-to-Capital 06/30/25 - - 03/31/25 - 89.99 12/31/24 - 48.04

Powered by Zacks Investment Research ©